• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Adagio Medical Holdings Inc

    2/17/26 4:00:03 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care
    Get the next $ADGM alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Adagio Medical Holdings, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    00534B100

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00534B100


    1Names of Reporting Persons

    Perceptive Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    15,321,655.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    15,321,655.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    15,321,655.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    57.5 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    00534B100


    1Names of Reporting Persons

    Joseph Edelman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    15,321,655.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    15,321,655.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    15,321,655.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    57.5 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    00534B100


    1Names of Reporting Persons

    Perceptive Life Sciences Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    15,120,753.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    15,120,753.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    15,120,753.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    56.8 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    00534B100


    1Names of Reporting Persons

    C2 Life Sciences LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    200,902.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    200,902.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    200,902.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Adagio Medical Holdings, Inc.
    (b)Address of issuer's principal executive offices:

    26051 Merit Circle, Suite 102, Laguna Hills, CA 92653
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.0001 par value per share (the "Common Stock") of Adagio Medical Holdings, Inc. (the "Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund") (iv) C2 Life Sciences LLC ("C2")
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003
    (c)Citizenship:

    Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation. C2 is a Delaware limited liability company.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    00534B100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages are based on 21,179,637 outstanding shares of Common Stock as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2025, and assume the exercise of warrants held by the Reporting Persons for 5,445,069 shares of Common Stock (the "Warrants"). The Master Fund is the holder of record of (i) 9,675,684 shares of Common Stock and (ii) Warrants exercisable for 5,445,069 shares of Common Stock. C2 is the holder of record of 200,902 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and C2, and Mr. Edelman is the managing member of Perceptive Advisors. Accordingly, Perceptive Advisors and Mr. Edelman have voting and investment discretion with respect to, and may be deemed to beneficially own, the shares of Common Stock and Warrants held of record by the Master Fund and C2.
    (b)Percent of class:

    Perceptive Advisors: 57.5% Mr. Edelman: 57.5% Master Fund: 56.8% C2 Life Sciences LLC: 0.8%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0 C2: 0

     (ii) Shared power to vote or to direct the vote:

    Perceptive Advisors: 15,321,655 Mr. Edelman: 15,321,655 Master Fund: 15,120,753 C2: 200,902

     (iii) Sole power to dispose or to direct the disposition of:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0 C2: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Perceptive Advisors: 15,321,655 Mr. Edelman: 15,321,655 Master Fund: 15,120,753 C2: 200,902

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Perceptive Advisors LLC
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:02/16/2026
     
    Joseph Edelman
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman
    Date:02/17/2026
     
    Perceptive Life Sciences Master Fund, Ltd.
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:02/17/2026
     
    C2 Life Sciences LLC
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:02/17/2026
    Get the next $ADGM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADGM

    DatePrice TargetRatingAnalyst
    12/2/2025$4.00Buy
    Lake Street
    More analyst ratings

    $ADGM
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Adagio Medical Holdings Inc

    SCHEDULE 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    2/17/26 8:13:15 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Adagio Medical Holdings Inc

    SCHEDULE 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    2/17/26 4:32:15 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Adagio Medical Holdings Inc

    SCHEDULE 13G/A - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    2/17/26 4:00:03 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Small Cap Growth Virtual Investor Conference: Presentations Now Available for On-Demand Viewing

    NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Small Cap Growth Virtual Investor Conference, held February 5th are now available for on-demand viewing. Individual investors, institutional investors, advisors, and analysts are invited to attend.REGISTER AND VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through February 10th. Please Schedule 1x1 Meetings here Febru

    2/6/26 8:35:00 AM ET
    $ADGM
    $COCH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    New Adagio Medical Publication Highlights Consistent Safety and Effectiveness with Ultralow Temperature Ablation in Broad Range of Patients with Ventricular Tachycardia

    Early Feasibility Outcomes in a Real-World Patient Cohort of Both Ischemic and Challenging Non-Ischemic Patients Published in Circulation: Arrhythmia and Electrophysiology Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the publication of results from the U.S. Early Feasibility Study ("EFS") evaluating ultralow temperature cardiac ablation ("ULTC") for the treatment of scar-related ventricular tachycardia ("VT"). The study was published in Circulation: Arrythmia and Electrophysiology. The prospective, multi-center study was conducted under the U.S. Food

    2/4/26 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Small Cap Growth Virtual Investor Conference Agenda Announced for February 5th

    NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for the Small Cap Growth Virtual Investor Conference to be held February 5th. Individual investors, institutional investors, advisors, and analysts are invited to attend.REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. Please Schedule 1x1 Meetings Here "We are proud to highlight this diverse roster of companies that demonstrate the innovation taking pl

    2/2/26 8:35:00 AM ET
    $ADGM
    $COCH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    $ADGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Kaster Deborah bought $17,973 worth of shares (15,000 units at $1.20) (SEC Form 4)

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    12/18/25 6:00:11 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Usen Todd bought $225,973 worth of shares (207,315 units at $1.09) (SEC Form 4)

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    12/15/25 9:24:15 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Salmon Sean

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    12/11/25 9:51:26 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Adagio Medical Holdings with a new price target

    Lake Street initiated coverage of Adagio Medical Holdings with a rating of Buy and set a new price target of $4.00

    12/2/25 8:38:52 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Kaster Deborah bought $17,973 worth of shares (15,000 units at $1.20) (SEC Form 4)

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    12/18/25 6:00:11 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Usen Todd bought $225,973 worth of shares (207,315 units at $1.09) (SEC Form 4)

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    12/15/25 9:24:15 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Adagio Medical Holdings Inc

    SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    11/13/24 4:30:17 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Adagio Medical Holdings Inc

    SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    8/12/24 4:22:57 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Leadership Updates

    Live Leadership Updates

    View All

    Adagio Medical Appoints Two Seasoned Senior Executives to Accelerate Commercial Readiness

    Marie-Claude Jacques appointed Senior Vice President, Global Sales; Antwan Gipson joins as Senior Vice President, Manufacturing & Operations Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced two key additions to its senior leadership team: Marie-Claude Jacques as Senior Vice President, Global Sales and Antwan Gipson as Senior Vice President, Manufacturing and Operations. "These appointments represent a significant milestone as Adagio prepares for commercialization of our proprietary Ultra-Low Temperature Cardiac Ablation technology ("ULTC") for electrophys

    12/22/25 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical Appoints Industry Veteran Sean Salmon to Board of Directors

    Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Sean Salmon has been appointed to its Board of Directors. Mr. Salmon will also serve on the Company's Audit Committee and Compensation Committee. Mr. Salmon, 60, recently retired from Medtronic after a distinguished, 20+ year tenure during which he held multiple senior global leadership roles across the company's cardiovascular and diabetes businesses. Most recently, he served as Executive Vice President and President of Medtronic's Cardiovascular Portfolio, which includes the Cardiac Rhythm, Cardiac Abl

    12/11/25 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical Reports Third Quarter 2025 Results

    Continued Momentum Toward PMA Submission of ULTC Technologies Recent Financing Positions Company to Execute Growth Strategy Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2025. Recent Business Highlights: Closed a private placement on October 20, 2025, with gross proceeds of up to $50 million, led by a syndicate of healthcare-dedicated institutional investors; upfront proceeds of approximately $19 million expected to fund FDA submission activities and ongoing next generation catheter deve

    11/12/25 4:05:00 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care